Axsome Therapeutics (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) conditions. Their operations span the entire drug development process, from discovery through clinical trials, with a mission to improve the lives of patients suffering from disorders and diseases affecting the brain and the nervous system. Projects in their pipeline include treatments for major depressive disorder, Alzheimer's disease agitation, and chronic pain, among others. The objective of Axsome is to bring innovative and effective therapeutic solutions to market, addressing unmet medical needs within the realm of CNS disorders, thereby enhancing patient care and outcomes.